Glancy Prongay & Murray LLP Commences Investigation on Behalf of Mylan NV Investors Concerning Recent Revelations Regarding A...
November 03 2016 - 6:51PM
Business Wire
Glancy Prongay & Murray LLP (“GPM”) announces an
investigation on behalf of Mylan NV (“Mylan”) or the “Company”)
(NASDAQ: MYL) investors concerning recent reports that the Company
has unlawfully colluded with other pharmaceutical companies to fix
generic drug prices.
According to news reports United States prosecutors may file
criminal charges against Mylan by the end of 2016 for suspected
price collusion.
Bloomberg News has reported that the, “antitrust investigation
by the Justice Department, begun about two years ago, now spans
more than a dozen companies and about two dozen drugs, according to
people familiar with the matter. The grand jury probe is
examining whether some executives agreed with one another to raise
prices, and the first charges could emerge by the end of the year,
they said.”
The companies identified as targets or relevant parties in the
United States investigation include Mylan NV, Teva Pharmaceutical
Industries Ltd, Allergan Plc, Lannett Co., Impax Laboratories Inc.,
Sun Pharmaceutical Industries Ltd., Mayne Pharma Group Ltd., Endo
International Plc and Taro Pharmaceutical Industries Ltd.
On this news, Mylan stock fell $2.53 per share, or nearly 7%, to
close at $34.14 per share on November 3, 2016.
If you purchased Mylan securities, have information or would
like to learn more about these claims, or have any questions
concerning this announcement or your rights or interests with
respect to these matters, please contact Lesley Portnoy, Esquire,
of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California
90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to
shareholders@glancylaw.com, or visit our website at
http://www.glancylaw.com. If you inquire by email please include
your mailing address, telephone number and number of shares
purchased.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161103006898/en/
Glancy Prongay & Murray LLP, Los Angeles/New YorkLesley
Portnoy, 310-201-9150 or
888-773-9224shareholders@glancylaw.comwww.glancylaw.com
Mylan NV (NASDAQ:MYL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mylan NV (NASDAQ:MYL)
Historical Stock Chart
From Sep 2023 to Sep 2024